QUINOLINE-OXAZOLINE COMPOUNDS AND THEIR USE IN OXIDATION SYNTHESIS
申请人:Sigman Matthew Scott
公开号:US20110054176A1
公开(公告)日:2011-03-03
A quinoline-oxazoline compound having the formula:
where one of X
1
and X
2
is N and the other is C and one of R1, R2 and R3 is Z wherein Z is an oxazoline radical having the formula
such that when X
1
is N R2 is Z and R1 is absent, and when X
2
is N either R1 or R3 is Z and R2 is absent. R1 and R3 through R12 are independently H or a pendant moiety which does not interfere with coordination of either N in the quinoline compound with a coordination center. These compounds can be complexed with a suitable coordination center such as catalytically active palladium and can be highly useful in catalytically oxidizing alkenes with high regioselectivity.
PREPARATION AND USE OF ORTHO-SULFONAMIDO ARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE INHIBITORS
申请人:American Home Products Corporation
公开号:US20020169184A1
公开(公告)日:2002-11-14
Ortho-sulfonamido aryl hydroxamic acids are provided which are useful, inter alia, for the inhibition of matrix metalloproteinases and the treatment of conditions associated with overexpression of MMPs.
Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors
申请人:Nelson Christy Frances
公开号:US20050085504A1
公开(公告)日:2005-04-21
Ortho-sulfonamido aryl hydroxamic acids are provided which are useful, inter alia, for the inhibition of matrix metalloproteinases and the treatment of conditions associated with overexpression of MMPs.
The preparation and use of ortho-sulfonamido arylhydroxamic acids as matrix metalloproteinase inhibitors
申请人:Wyeth
公开号:US20030035332A1
公开(公告)日:2003-02-20
Ortho-sulfonamido aryl hydroxamic acids are provided which are useful, inter alia, for the inhibition of matrix metalloproteinases and the treatment of conditions associated with overexpression of MMPs.
Preparation and use of ortho-sulfonamido arylhydroxamic acids as matrix metalloproteinase inhibitors
申请人:Wyeth
公开号:US06825352B2
公开(公告)日:2004-11-30
Ortho-sulfonamido aryl hydroxamic acids are provided which are useful, inter alia, for the inhibition of matrix metalloproteinases and the treatment of conditions associated with overexpression of MMPs.